• Mar 14, 2025

3 Reasons IART is Risky and 1 Stock to Buy Instead

While the broader market has struggled with the S&P 500 down 1.3% since September 2024, Integra LifeSciences has surged ahead as its stock price has climbed by 31.6% to $22.79 per share. This performance may have investors wondering how to approach the situation.

  • Mar 14, 2025

3 Reasons to Sell ELAN and 1 Stock to Buy Instead

Elanco has gotten torched over the last six months - since September 2024, its stock price has dropped 28.5% to $10.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.

  • Mar 14, 2025

3 Reasons SEM is Risky and 1 Stock to Buy Instead

The past six months haven’t been great for Select Medical. It just made a new 52-week low of $15.71, and shareholders have lost 55.5% of their capital. This was partly due to its softer quarterly results and might have investors contemplating their next move.

  • Mar 14, 2025

3 Reasons to Avoid CRM and 1 Stock to Buy Instead

Even during a down period for the markets, Salesforce has gone against the grain, climbing to $274.18. Its shares have yielded a 6.7% return over the last six months, beating the S&P 500 by 8%. This run-up might have investors contemplating their next move.

  • Mar 14, 2025

3 Reasons COMP is Risky and 1 Stock to Buy Instead

Even during a down period for the markets, Compass has gone against the grain, climbing to $8.75. Its shares have yielded a 36.5% return over the last six months, beating the S&P 500 by 37.8%. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.